Avida Health Pte Ltd announces that it has entered a distributor deal with New Zealand functional ingredient supplier Anagenix for sales and marketing of the latter’s products, namely Actazin®, Livaux® and BerriQi®, in selected Southeast Asian markets since end-2020.

Actazin® is a natural functional food ingredient derived from New Zealand green kiwifruit. It is clinically proven to improve bowel regularity and digestive health.

Livaux® is a unique and innovative prebiotic ingredient derived from New Zealand gold kiwifruit. It is scientifically proven to improve gut microbiome with specific targeting for F. prau. Healthy F. prau levels are important in managing gut conditions such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). Livaux® is also a double winner at 2020’s Nutraingredients-USA and Nutraingredients-Asia awards (Prebiotic of the Year).

BerriQi® is a natural fruit concentrate made from New Zealand boysenberry. It is scientifically proven to aid lung health and repair. Recent evidence showed that it could potentially help with lung tissue recovery in lung fibrosis patients. BerriQi® is also available as a powder grade.

Avida Health is appointed as the exclusive distributor for Actazin® in Indonesia and Philippines, and for BerriQi® in Indonesia, Philippines and Vietnam. Avida Health is also an authorized agent for Livaux® in Indonesia and Philippines.

These products expand Avida’s portfolio of specialty ingredients for gut health and immune health. Both companies are looking into establishing greater market presence in Southeast Asia through this partnership.

Related posts